A long-acting agent with no known drug-drug interactions1

In in vitro studies, no antagonism has been observed between Xydalba and other commonly used antibiotics:

Clinical drug-drug interaction studies with Xydalba have not been conducted1

  • Xydalba is not metabolized by CYP enzymes in vitro, therefore co-administered CYP inducers or inhibitors are unlikely to influence the pharmacokinetics of Xydalba
  • The interaction potential of Xydalba on medicinal products metabolized by CYP enzymes is expected to be low since it is neither an inhibitor nor an inducer of CYP enzymes in vitro

It is not known if Xydalba is a substrate for hepatic uptake and efflux transporters1

  • Co-administration with inhibitors of these transporters may increase the exposure to Xydalba

It is not known if Xydalba is an inhibitor of transporters1

  •  Increased exposure to transporter substrates sensitive for inhibited transporter activity, such as statins and digoxin, cannot be excluded if combined with Xydalba

In in vitro studies, no antagonism has been observed between Xydalba and other commonly used antibiotics:

aztreonamcefepime
ciprofloxacinceftazidime
piperacillinceftriaxone
tazobactamimipenem
trimethoprimmeropenem
sulfamethoxazoleamikacin
1 Xydalba SmPC